GlaxoSmithKline has launched a multibillion pound restructuring drive, including a potential flotation of its HIV drugs business, in a push to win back shareholder support after a year marked by corruption allegations and faltering sales.
葛蘭素史克（GlaxoSmithKline，簡稱GSK）發起鉅額重組努力，包括可能讓愛滋病(HIV)藥物部門上市，試圖在經歷一年的腐敗指控和疲弱銷售後贏回股東的支持。
您已閱讀10%（321字），剩餘90%（2760字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。